Initial experience with the new ethylene vinyl alcohol copolymer based liquid embolic agent Menox in the endovascular treatment of cerebral arteriovenous malformations.
Stanimir SirakovAlexander SirakovKrasimir MinkinMarin PenkovKristian NinovHristo HristovVasil KarakostovRadoslav RaychevPublished in: Journal of neurointerventional surgery (2019)
Curative embolization in one endovascular session was achieved in 14/24 (58.3%) of the treated patients. Partial embolization was achieved in 10 patients (42.6%) in whom staged treatment with radiosurgery or microsurgical resection was planned. No mortality was recorded in our series. Clinical complications after embolization occurred in 1/24 (4.66%) patients. No technical complications were noted CONCLUSIONS: Our pilot study suggests that the Menox embolization system offers similar technical and clinical results in comparison with the other currently available LEAs. Further studies with larger cohorts and long term follow-up data are needed to fully evaluate its efficacy.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- endovascular treatment
- cardiovascular disease
- patient reported outcomes
- coronary artery disease
- drug delivery
- subarachnoid hemorrhage
- brain injury
- artificial intelligence
- smoking cessation
- big data
- working memory
- cardiovascular events
- replacement therapy